MLS on the verge of breaking above that 31p high of April 2002. This was the item that triggered the current breakout last week:

LONDON (AFX) - Medical Solutions PLC, the cancer and pathology services
group, said The Doctors Laboratory, the leading provider of private cervical
screening in the UK, has stated that they are adopting Medical Solutions'
SurePath for their LBC screening.
The SurePath system will be supplied by Medical Solutions in the UK under
licence from TriPath Imaging Inc.
Medical Solutions chief executive Charles Green said the group now awaits
the NICE (the National Institute of Clinical Excellence) report issuing their
final guidance to the NHS, after their preliminary report recommended the use of
liquid based cytology within the NHS. This report is expected in September.
newsdesk@afxnews.com
slm/

See impressive bb comment here since then and on various BBs.

Interims due mid-Sept.
Ahead of a long weekend there might yet be some profit-taking, but with results and statements to come within the next 2-3 weeks I would guess most who are planning to do so will reduce rather than exit, and the effect will be perhaps be outweighed by new buyers waking up to what's happening.

MLS don't have the field to themselves with the nhs - there are still other contenders in the running. But it's looking hopeful in my opinion.

Company website

External Shareholders at 21 Aug 03:
89.15m 2p Ords - Edinburgh Fund Mgrs PLC 6.32%, INVESCO Asset Mgmt Ltd 5.78%, Prudential PLC 5.61%, Cantor Fitzgerald Europe 5.34%, Texas Group PLC 4.12%, Singer & Friedlander Inv 3.45%, Other Dirs 1.65%.

jzl

GREAT NEWS FOR YOU/SHAREHOLDERS
Up 8.50 / 17.99 per cent @ 4,736,092 million volume
I forget the www I found it.
................................
More info:
www.moneyextra.com/stocks/LSE/MLS---------Click company news.

Plenty of favourable press coverage this weekend so far. Some profit-taking was to be expected yesterday at the end of such a positive week, but the share price soaked up those sells with ease.

Analysts and brokers newly alerted to this stock by the nhs and related government statement should be coming up with upgrades soon. Plus the possibility of it becoming a very tasty takeover target now that it looks like taking a fair chunk of that nhs business. Not that it is reliant on the LBC cervical cancer testing work. It has several solid divisions (expect some newsflow from those between now and end of year).

Sonic (Australian Top-100 company) has an active connection with MLS on several fronts and is considered by many to be a likely bidder at some stage.

jzl

Some more on Sonic - lifted from an excellent piece by S-H-B on another BB:

..Sonic is the largest medical diagnostics Company in Australasia and New Zealand, providing quality Pathology and radiology services in the community.

...has made rapid progress and turnover is now almost 1billion AUS dollars.

Sonic Stategy:
Capture synergies with Sonic pathology
Build relationships with independent healthcare entities
Acquisitions
UK pathology opportunities
European pathology

Sonic Statement:
The group’s UK operation, TDL, continues to perform strongly, with significant growth in both revenue and EBITA. Recent developments in the UK include the acquisition of the Omnilabs pathology group in July 2003 and the announcement of a strategic joint venture with the University College London Hospital (UCLH), one of the UK’s most prestigious teaching hospitals. TDL (including the merged Omnilabs operation), is expected to move into a new, state-of-the-art laboratory facility in December 2003 and will partner with UCLH to form a high-volume automated laboratory in the new facility for the routine pathology testing of both entities.

Dr Goldschmidt said that the UCLH joint venture represented an important milestone in Sonic’s history. “We are privileged to work with UCLH and we anticipate that the relationship will bring benefits to both groups at many levels. The TDL/UCLH joint venture will create the platform for growth in both the public and private pathology markets in the UK"


As above, Sonic are very very keen to gain a major foothold in the NHS, and be part of the NHS Pathology modernisation plan this has been achieved with having contracts with the NHS through TDL, and now having very close ties with MLS who are firmly established throughout the NHS, this puts Sonic now in the position as a 'stalking horse' waiting for the opportune moment to make their move on MLS.

Karol Sikora is an advisor for Astra Zeneca and does work for HCA a large US Healthcare company, But Sonic are purely a diagnostics company who have a foothold in the UK market and with Medicals business operations would be an ideal synergistic fit for Sonic.

Detailed info about Sonic and Company stategies can be found on this link
http://www.sonichealthcare.com/sonic/internet/html_corporate/index.html

2004 saw Medical Solution go from Greatness to Weakness, yet here there are no comments - - -

This stock has got to be a one way bet, it'll go back up as fast as it fell as soon as some news is out. Any thoughts on this one's future

20 times as many buys as sells today, and previous days. Something big is coming soon

snaylor

Clearly, the placing has gone well. My information is that the new board members have been well received. The city has clearly backed them in seeing off the hostile bid. Thus it is seen that the company should recover. I doubt whether there has been time for any trading improvement. Rather, the fall was overdone.

Eric

Fascinated at the lack of comment on this bb. Positive news out to day with Surepath sales. Successful fundraising behind them. Strong new board members on board. Focussing on getting the finances in order. What is more: Evil Knievel has a LONG position in MLS. Anyone with inside view of the market?

Eric

Another post to repeat the question of the last one to keep it on top page. I will go on doing this until I get an answer! Can anyone tell me what this company is worth?

Eric

Not me;- but I did buy-in a lot higher in the days when they were about to gain NHS money, which I understand has been their downfall.
/
When a co really disapoints it takes a lot of positive news (over a sustained time) to convince folk that the company is worthwhile. I haven't subscribed recently as it was too close to the market price IMHO. The drift down more-or-less confirms this. Maybe a new strategy is in order, but the sp will not react until it shows some results.
Keep asking the questions, EWRobson - someone must know.

Thanks, hangon. I think you are right re the need for sustained good news. There are many AIM companies way down from their best and below placing prices. There doesn't appear to be much hot money there for breaking positive stories either. You keep wondering whether companies like MLS, YOO and CYH can drift lower and they do, because of lack of buyers.

Would also appreciate others views on this stock and think you are both correct re the need for continual good news.

From my understanding MLS is not an Aim stock.

Thanks for trying to keep this on the top page.

Sorry, the same old chap and not another! Just been looking at the Hemscott figures and the updated broker forecasts. Charles Stanley, house broker, have reduced from Buy to Hold. What is more, or less, they are not forecasting profits in the next two financial years. So I doubt if tis a buy this time of the summer recess - there's so much more positive around which is not moving. Hold might be OK because price might just bobble along the bottom for a while.

Eric

8 June 2006

Medical Solutions plc

("Medical Solutions" or "the Group")

Annual General Meeting

Sir Gareth Roberts, Chairman of Medical Solutions plc will be making the
following statement at the 2006 Annual General Meeting today:

"Following the significant improvement in the Group's financial and operating
performance during 2005, I am pleased to report that excellent progress has
been made during the early part of 2006.

Trading update

We stated in our 2005 Annual Report that we had targeted sales growth rates of
around 20-25% for the year ending 31 December 2006 and I am delighted to report
that, over the early part of the year, this is a target that we have exceeded.
Our operating costs remain under control and our cash position has been well
managed.

This is good news for the future, probaly why someone bought significant 1m recently.

A good post from AFN, which may be linked to EK and talk about Cancer treatments etc.. that might be throwing lots of lots of money the way of MLS..


Rex Taurus - 9 Jun'06 - 09:47


From yesterday's AGM statement:


In the UK Diagnostic Pathology business, progress during the early part of the
year has been excellent following the continued high demand experienced for our
service offerings, including the Her 2 test, designed to establish whether or
not a patient suffering with breast cancer will respond to the drug
HerceptinTM.



Today's News:

http://icwales.icnetwork.co.uk/0100news/0200wales/tm_objectid=17201787&method=full&siteid=50082&headline=-thousands-of-lives-saved--as-herceptin-approved-for-nhs-name_page.html

'Thousands of lives saved' as Herceptin approved

Notice of Results

RNS Number:1211I
Medical Solutions PLC
25 August 2006


Medical Solutions plc

Notice of Interim Results

Medical Solutions plc, the provider of pathology and cytology products and
services to the healthcare and pharmaceuticals sector, will announce interim
results for the six months ended 30 June 2006 on Thursday 31 August 2006.

-Ends-

For further information:

Medical Solutions
Neil Johnston 0115 973 9010

Bell Pottinger
Geoff Callow/Chris Hamilton 020 7861 3232




This information is provided by RNS
The company news service from the London Stock Exchange

Heck, did I really start this thread??
It was OK for about 2 months from then :-o

And I was so much younger and innocent..

Great set of results, reports maiden profit....

Interim Results

RNS Number:2764I
Medical Solutions PLC
31 August 2006



For further information, please contact:
Medical Solutions plc
Neil Johnston
Tel: 0115 973 9010
www.medical-solutions.co.uk

Bell Pottinger Corporate & Financial
Geoff Callow/Chris Hamilton
Tel: 0207 861 3232



Medical Solutions plc

Interim results for the six months ended 30 June 2006


Medical Solutions plc (LSE: MLS), the provider of pathology and cytology
services and products to the healthcare and pharmaceuticals sectors, announces
its unaudited interim results for the six months ended 30 June 2006.


Financial Highlights

* Turnover from continuing operations up 36% to #6.8 million (H1 2005:
#5.0 million)

* Achievement of maiden operating profits of #66,000 (H1 2005: operating
loss of #1.0 million)

* Cash generative during period; net cash of #2.7 million at 30 June 2006
(31 December 2005: #2.3 million)

* Net profit for the period of #26,000 (H1 2005: net loss of #1.1 million)

Operational Highlights


* Advanced discussions in progress regarding the proposed sale of the
Group's Dubai business

* Liquid Based Cytology ("LBC") exclusive distribution agreement with
Tripath Imaging, Inc. renewed until 31 December 2010

* LBC 45% target market share (England and Wales) now achieved; further
contracts yet to be awarded

* New products launched in UK Diagnostic Pathology and Drug Development
Services divisions

* Currently supporting key UK trials designed to evaluate automated
cervical smear screening, a major potential growth market

Board changes

* Charles Green steps down as Chief Executive Officer with immediate
effect; Neil Johnston appointed as Chief Executive Officer, Nick Ash appointed
as Chief Financial Officer

Sir Gareth Roberts, Chairman, said:

"We have made an excellent start to the year and have achieved a profitable,
cash generative position for the first time. Discussions regarding the proposed
sale of the Dubai business have also been positive and we expect to be able to
make a further announcement on this subject in the near future.

As part of a planned succession, Charles Green will be stepping down as Chief
Executive Officer and Neil Johnston has been appointed as his successor, both
with immediate effect. Dr Nick Ash, previously Group Financial Controller, has
been appointed to the Board of Directors as Chief Financial Officer. On behalf
of the Board, I would like to express our thanks to Charles for all his efforts
during his time with Medical Solutions plc and wish him well in the future."

Chairman's Statement

Introduction

During the first half of 2006, we have continued to focus on our key short term
objectives, namely profitability and cash generation. I am delighted to report
that both objectives have been achieved for the six months ended 30 June 2006.

Financial and Operational Review

Financial Review

Turnover for the six months ended 30 June 2006 increased by 36% to #6.8 million
compared with #5.0 million in the first half of 2005. This is our third
successive period in which we have demonstrated strong revenue growth. The
increase in turnover during the period has been driven primarily by growth in
our Cytology division and in Dubai with revenues having increased by 90% and 55%
respectively.

Gross margins have improved from #1.9 million (39%) for the first six months of
2005 to #2.8 million (41%) as a result of further improvements in the efficiency
of our operations during the period.

Operating expenses (excluding exceptional restructuring costs and gains on sales
of fixed assets) have decreased to #2.7 million for the six months ended 30 June
2006 from #3.1 million during the same period in 2005. Operating expenses for
the period also include a charge of #0.1 million relating to a share option
based compensation charge as required by IFRS 2 (H1 2005: #0.1 million). These
savings have been achieved through a combination of further efforts to improve
the efficiency of our operations and the ongoing effects of decisions taken
during 2005, such as the closure of the Harley Street facility. No taxation
charge has been recognised in the period (H1 2005: #nil) as the profits of the
Dubai operations are not subject to taxation locally and the Group has tax
losses available to offset profits in the UK.

Net cash inflow from operating activities during the six months ended 30 June
2006 was #0.8 million (H1 2005: cash outflow of #1.8 million). Capital
expenditure of #0.2 million was incurred during the period (H1 2005: #0.2
million) in connection with LBC machines and laboratory equipment in the UK and
Dubai and we have repaid borrowings (including minority interests) of #0.2
million. The Group had a net cash balance of #2.7 million as at 30 June 2006 (31
December 2005: #2.3 million).

Operational Review

Pathology Services

UK Diagnostic Pathology ("UKDP")

Overall sales in H1 2006 have been consistent with those achieved in H1 2005 at
#1.3 million. This masks the underlying improvement in this area of our
business. We have seen higher volumes of specialist testing through our
Reference Laboratory during the period, which has offset 2005 revenues in the
Virtual Microscopy area (#0.2 million), which we have since exited.

We have continued to demonstrate improvements in the profitability of this part
of our business. UKDP generated an operating profit of #337,000 during the
period (a 26% return on sales) compared with #102,000 in H1 2005, the latter
including a #387,000 one-off profit on the sale of certain intellectual property
rights.

During the second half of 2006 we are looking to develop this area of our
business through investment in new specialist testing services in the cancer
area and an increase in the size of our UK business development team.


Over the next few years, we see major opportunities to grow our UKDP business
through partnerships with the NHS. The recent review of NHS Pathology Services
by Lord Carter of Coles was clear in envisaging the potential for significant
benefit from further involvement of the independent sector in the provision of
pathology services in England.

Dubai Diagnostic Pathology

Our business in Dubai has continued to perform strongly. Sales are up by 55% to
#3.6 million from #2.3 million primarily due to the continued positive impact of
the Labour Medical Testing programme being conducted by Specialised Clinical
Laboratory ("SCL") in conjunction with the UAE Government. Operating profits
have improved from #0.7 million in H1 2005 to #1.3 million in H1 2006.

In March 2006, we announced that we had reached agreement with representatives
of the Varkey Group and Welcare Hospital to settle the outstanding #2.5 million
contingent deferred consideration, recognised as a provision in the consolidated
balance sheet, relating to the acquisition of the Welcare Laboratory in 2003 and
to recover the #0.9 million owed to Medical Solutions by Welcare Hospital. In
May 2006, we announced that we believed that this transaction would be completed
as part of a sale of the whole of the Group's interests in Dubai.

Drug Development Services ("DDS")

Sales in our DDS business have been disappointing mainly as a result of a
reduced level of business from AstraZeneca compared with the same period in
2005. We reduced our annual direct costs significantly during 2005 and our
annual cash investment during 2006 is expected to be around #0.6 to #0.7 million
bringing a cash breakeven result within reach.

We have introduced a new service offering based on Circulating Tumour Cell
("CTC") technology in May and announced our first contract with an undisclosed
major pharmaceutical company. We are hopeful of further contracts in this area.

On the basis of a relatively low ongoing investment in DDS and our belief that
this customer base will be an important part of our growth as our business
develops, it is our current intention to retain this part of our business.

Cytology

The Cytology division has performed strongly during the six months ended 30 June
2006. Sales have increased to #1.7 million from #0.9 million, a 90% increase.
Operating profits have improved to #262,000 in H1 2006 from a small loss of
#26,000 during H1 2005. During the period we have announced an agreement with
the Hereford and Telford Processing and Screening Laboratories Network. We have
also begun to supply two other regions in the Midlands area. As a result of
these business gains, we have achieved our targeted LBC market share in England
and Wales of 45%. We expect further contract wins in this part of our business.

We have also signed a further extension to our exclusive LBC distribution
agreement for the UK and Ireland with Tripath Imaging, Inc. ("Tripath"),
extending the original agreement until 31 December 2010.

In partnership with Tripath, we are currently supporting two UK based trials
designed to evaluate an automated approach to cervical screening. This
technology is already being used successfully in other European countries and
has the potential to revolutionise the efficiency of the current screening
process. This is of particular importance in the UK at present given the severe
pressures faced by laboratories in achieving adequate staffing levels resulting
in lengthy turnaround times for results. We are particularly excited about the
future of automated screening and are reviewing alternative business models
through which we can maximise shareholder value.

Update on planned sale of Dubai Diagnostic Pathology

We previously announced our decision to exit from our business in Dubai in order
to focus on and invest in, our UK operation and maximise its potential. Since we
last reported, we have continued discussions with a number of different parties
who have expressed interest in our Dubai operation. We are currently in advanced
discussions with our preferred purchaser and expect to make a further
announcement on this subject in the near future.

Board Changes

With immediate effect, Mr Charles Green will step down as Chief Executive
Officer. As part of the planned succession, Dr Neil Johnston has been appointed
as Chief Executive Officer and Dr Nick Ash, who joined the Group during 2005 as
Group Financial Controller, will become Chief Financial Officer. Mr Green will
remain with the Dubai business on a consultancy basis for an interim period.

Prospects

During the six months ended 30 June 2006, we have made further progress and have
achieved our immediate targets of profitability and cash generation. We are not
complacent about the challenges that lie ahead but we look forward to the future
with renewed optimism based upon the continued improvement in our financial
performance and the significant market opportunities which await.

Sir Gareth Roberts
Chairman
31 August 2006

Rodders